Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2008

Filing Date
Filed February 4, 2009
Period End
December 31, 2008
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 4, 2009. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NBIX) reports a net loss of $88.6 milliona for 2008, compared with $207.3 million in 2007 and $107.2 million in 2006.

The 2007 loss included a $94.0 millionb non-cash impairment of a prepaid royalty on indiplon. Total revenues were $4.0 million in 2008 versus $1.2 million in 2007, and the company states it has not generated revenue from product sales and does not expect to be profitable in 2009 or the foreseeable future. The accumulated deficit reached $703.3 million at December 31, 2008.

Cash, cash equivalents and short-term investments were $80.5 millionc at year-end, with long-term investments of $21.1 million including $18.7 million of auction rate securities at carrying value, and the company states that existing resources should be sufficient for at least the next 12 months. The company's pipeline centers on elagolix, an oral GnRH antagonist in Phase II for endometriosis, with Phase III trials expected to begin in early 2010 if the end-of-Phase II meeting with the FDA proceeds as planned. Its CRF programs are partnered with GlaxoSmithKline, and indiplon for insomnia has an FDA approvable letter for 5mg and 10mg capsules that carries new requirements, after which the company ceased U.S. indiplon clinical development activities.

The company also reported restructuring activities, including a $15.7 milliond cease-use expense tied to the front building of its San Diego headquarters, and it expects research and development and SG&A expenses to decrease in 2009. The filing also discloses that the company had approximately 125 employees as of January 31, 2009, and that securities class action and derivative litigation related to indiplon were dismissed in late 2008. Investors should weigh the company's continued losses, dependence on collaborators, and regulatory uncertainty around indiplon against its late-stage elagolix program and existing collaboration income.

Key Highlights

  1. Net loss of $88.6 million for 2008, down from $207.3 million in 2007, which included a $94.0 million prepaid royalty impairment; net loss per share was $2.30 versus $5.45.
  2. Total revenues of $4.0 million in 2008 compared with $1.2 million in 2007 and $39.2 million in 2006; the company has not yet generated revenue from product sales.
  3. Accumulated deficit of $703.3 million at December 31, 2008, and the company does not expect to be profitable in 2009 or the foreseeable future.
  4. Cash, cash equivalents and short-term investments of $80.5 million at year-end 2008, and the company believes existing resources will fund requirements for at least the next 12 months.
  5. Lead product candidate elagolix (oral GnRH antagonist) is in Phase II for endometriosis; a Phase IIb study met its primary bone mineral density endpoint, and Phase III trials are expected to begin in early 2010.
  6. Indiplon received a 2007 FDA approvable letter for 5mg and 10mg capsules with new requirements, and the company ceased U.S. indiplon clinical development and pre-commercialization activities; Dainippon Sumitomo Pharma holds a Japan license with a $20.0 million upfront fee.
  7. Auction rate securities carried at $18.7 million on $22.6 million par value, with $14.6 million of par value maintained by UBS subject to ARS Rights exercisable from June 30, 2010 to July 2, 2012.

Frequently Asked Questions

  1. Why did the net loss decline sharply in 2008?

    The 2007 net loss of $207.3 million included a $94.0 million non-cash impairment of a prepaid royalty on indiplon. The 2008 net loss of $88.6 million reflected lower research and development expense ($55.3 million versus $82.0 million), lower sales, general and administrative expense ($20.2 million versus $37.5 million), and a $15.7 million cease-use expense for the headquarters front building.

  2. Does Neurocrine expect to be profitable soon?

    No. The filing states the company does not expect to be profitable for the year ending December 31, 2009 or the foreseeable future, and expects to continue incurring losses and negative cash flow, with research and development and SG&A expenses expected to decrease in 2009.

  3. How is the company funded and is additional capital needed?

    The company believes its existing capital resources, investment income and future payments under strategic alliances will be sufficient for at least the next 12 months. It has an effective shelf registration allowing up to $150 million in common stock offerings, but notes that equity or debt financing may not be available on reasonable terms.

  4. What is the status of the indiplon program?

    The FDA issued an approvable letter in December 2007 for indiplon 5mg and 10mg capsules, requiring an elderly clinical trial, a safety study comparing adverse event rates to a marketed product, and a preclinical third-trimester pregnancy study. The company held an end-of-review meeting in July 2008, is awaiting final minutes, and has ceased U.S. clinical development. The 15mg tablets received a Not Approvable Letter.

  5. What are the key near-term catalysts for elagolix?

    The company expects top-line results from a first additional Phase IIb trial in the first quarter of 2009, top-line data from a second trial in the third quarter of 2009, an end-of-Phase II meeting with the FDA in late 2009, and Phase III trials to commence in early 2010. Additional data from the earlier Phase IIb study, including 6- and 12-month bone density scans, is expected during 2009.